Molecular classification of cancers of unknown primary site.

摘要: Cancer of unknown primary site is a common metastatic cancer, diagnosed in about 50 000 patients per year the US. The diagnosis, classification, and management with carcinoma has been difficult frustrating. therapy usually empiric for majority patients, their prognosis poor. Molecular classification cancers known sites accurate (76-89%), as reported from several studies. profiling initial biopsy specimens tremendous potential test to diagnose tumor origin cancer. Several retrospective studies molecular assays have provided indirect validation accuracy prediction, based on correlations clinicopathologic features. One additional study diagnostic biopsies cancer where were identified months years later, more direct (the 15 20 correctly predicted). ability classify precisely would allow site-specific or targeted therapy, likely improve patient outcomes. clinical are progress planned this concept.